Dr. Lal PathLabs Limited (LALPATHLAB) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹2,020.6 (+0.59% day change)
Key ratios
- P/E ratio
- 66.82
- P/B ratio
- 8.73
- ROE (%)
- 20.13
- ROCE (%)
- 23.03
- Debt/Equity
- 0.08
- Dividend yield (%)
- 1.02
- Market cap (₹ Cr)
- 33,786.6
Forensic checks
Piotroski F-Score: 4/9 · Altman Z-Score: 13.49 · Beneish M-Score: -2.58
InvestSights quality score
67.2/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Revenue growth: guided 11–12%, delivered 12.26% (FY26) — exceeded guidance
Latest earnings call (Q2 FY27)
AI summary: The most important signal was that management now expects FY27 revenue growth in the high teens, supported by broad-based patient additions, network investments and a temporary CGHS contribution of between 2 to 3%. Q2 revenue reached ₹874 crore, up 19.6%, while patient volume grew 9% and sample volume increased 13.6%. Operating leverage and test mix lifted EBITDA to ₹280…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.